1B. F. Gibbs,W. Schmutzler,I. B. Vollrath,P. Brosthardt,U. Braam,H. H. Wolff,G. Zwadlo-Klarwasser. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells[J] 1999,Inflammation Research(2):86～93
2A. Gillissen,A. Bartling,S. Schoen,G. Schultze-Werninghaus. Antioxidant Function of Ambroxol in Mononuclear and Polymorphonuclear Cells in Vitro[J] 1997,Lung(4):235～242
3R. R. Wauer,G. Schmalisch,B. B?hme,J. Arand,D. Lehmann. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome[J] 1992,European Journal of Pediatrics(5):357～363
4Maria Giulia Marini. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: Double-blind italian multicenter clinical study versus placebo[J] 1991,Lung(1):69～76
4Teksam O, Kale G. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome [ J ]. Pathol Res Pract,2009,205( 1 ) :35 -41.
5Mc Fetridge L, McMorrow A, Morrison PJ, et al. Surfactant metabolism dysfunction and childhood interstitial lung disease(chiLD) [ J]. Ulster Med J ,2009,78 ( 1 ) :7 - 9.
7Chotigeat U, Promwong N, Kanjanapattanakul W, et al. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods [ J ]. J Med Assoc Thai, 2008,91 (Suppl 3) :109 - 114.
8Aimsaad L, Diraphat P, Utrarachkij F, et al. Epidemiological characteristics of Acinetobacter baumannii infections at Phramongkutklao Hospital [ J ]. J Med Assoc Thai, 2009,92 ( Suppl 7 ) : 164 - 172.
9Ewig S, Bauer T, Torres A. The pulmonary physician in critical care * 4 : nosocomial pneumonia [ J ]. Thorax, 2002,57 (4) :366 -371.
10Nebeel K, Nancy B, John H, et al. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation[ J]. Pediatrics,2001,108( 1 ) :13 - 17.
